July 14, 2023
CMIC HOLDINGS Co., Ltd.
Our wholly-owned subsidiary CMIC Co., Ltd. (Head Office: Minato-ku, Tokyo; Akihisa Mitake, President and CEO; hereinafter referred to as “CMIC”) and CMIC Shift Zero K.K., the wholly-owned subsidiary of CMIC, (Head office: Minato-ku, Tokyo; President and Representative Director: Teruyoshi Okuda; hereinafter referred to as “CSZ”) resolved to integrate effective October 1, 2023, with CMIC as the surviving company, at their respective Board of Directors meetings held today.
1. Purpose and Overview of the Integration
As one of Japan’s largest CROs (Contract Research Organization), CMIC provides one-stop support services, including strategic consultation for pharmaceuticals in all therapeutic areas, development and post-marketing planning, regulatory filings, and post-marketing surveillance. As clinical trials are becoming increasingly sophisticated and complex, we have established a business structure by area (oncology, central nervous system, primary care, specialty care (regenerative medicine and rare diseases), post-marketing surveillance, clinical research, and medical devices) in line with trends in pharmaceuticals and other products, and are promoting the provision of more specialized and domain-specific solutions.
CSZ was established in January 2016 as a joint venture between CMIC HOLDINGS Co., Ltd. (Head Office: Minato-ku, Tokyo; Kazuo Nakamura, Chairman and CEO; hereinafter referred to as “CMIC HD”) and Shift Zero K.K. (Head office: Minato-ku, Tokyo; President and Representative Director: Kiyoshi Fujimaru). As a CRO specializing in the oncology field, we provide support services utilizing our network of opinion leaders in the oncology field and knowledge gained from collaborations with various research groups.
With the increase in oncology development, the two companies have established a collaboration scheme to smoothly execute project management and monitoring operations, led by experienced oncology development experts who have strong relationships of trust with KOLs (Key Opinion Leaders) in Japan and Asia in several projects. As the pipeline in the oncology field is expected to increase in the future, the two companies will combine their know-how and resources through this merger to further enhance their expertise and provide better services to their customers.
2. Summary of the integration
(1) Method of Integration
CSZ will be dissolved in an absorption-type merger with CMIC as the surviving company.
(2) Schedule of the integration
Effective date of the integration: October 1, 2023 (plan)
3. Overview of the Operating Companies
|(1) Trade name||CMIC Co., Ltd.||CMIC Shift Zero K.K.|
|(2) Location||1-1, Shibaura 1-chome, Minato-ku, Tokyo||1-1, Shibaura 1-chome, Minato-ku, Tokyo|
|(3) Name and title of representative||Akihisa Mitake
President, CMIC Co., Ltd.
President, CMIC Shift Zero K.K.
|(4) Main businesses||CRO Business
|(5) Capital||100 million yen||10 million yen|
|(6) Date established||January 4, 2012||January 15, 2016|
|(7) Accounting term||September 30||September 30|
|(8)Number of employees
(As of June 30, 2023)
|(9) Shareholders and holding ratios||CMIC HD 100%||CMIC 100%|
About CMIC Group
CMIC was founded in 1992 as the first contract research organization (CRO) in Japan. To enable pharmaceutical companies to develop better medicine sooner, we expanded our solutions to include contract development and manufacturing (CDMO), site support, and market solutions, supporting global companies to bring highly desired treatments to the Japanese market. CMIC has also entered into the healthcare arena. Leveraging our vast experience and expertise in the medical industry, we offer solutions using a new ecosystem of healthcare to support the individuals and local governments. We strive to be a Personal Health Value Creator (PHVC) to meet our global customers’ needs in the U.S., Japan, and broader Asia. CMIC Group has over 7,500 employees and 27 sites globally. For more information about CMIC Group and services, please visit our website: